1Baggstrom M,Socinski MA,Hensing T,et al.Third generation chemotherapy regimens (3GR) improve survival over second generation regimens (2GR) in stage ⅢB/Ⅳ non-small cell lung cancer (NSCLC):a meta-analysis of the published literature.Proc Am Soc Clin Oncol,2002,21:306a.
3Delbaldo C.Adding a second or a third drug to a chemotherapy regimen in patients with advanced non-small cell lung carcinoma (NSCLC):a meta-analysis of the lietrature.Proc Am Soc Clin Oncol,2003,22:623.
4Baggstrom M,Socinski MA,Hensing T,et al.Addressing the optimal number of cytotoxic agents in stage ⅢB/Ⅳ non-small cell lung cancer (NSLCC):a meta-analysis of the published literature.Proc Am Soc Clin Oncol,2003,21:306.
5Tiseo M,Boni L,Ardizzoni A.Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer:does cisplatin versus carboplatin make a difference? J Clin Oncol,2005,23:6276-6277.
6Fossella F,Devore R,Kerr R,et al.Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing regimens.The TAX 320 Non-Small Cell Lung Cancer Study Group.J Clin Oncol,2000,18:2354-2360.
7Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with nonsmall-cell lung cancer previously treated with chemotherapy.J Clin Oncol,2004,22:1589-1597.
8Pfister DG,Johnson DH,Azzoli GG,et al.American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline:update 2003.J Clin Oncol,2004,22:330-353.
9Winton TL,Livingston R,Johnson D,et al.A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10.J Clin Oncol,2004,22 Suppl 14:7018.
10Dunant A,Pignon JP,Le Chevalier T.Adjuvant chemotherapy for non-small cell lung cancer:contribution of the International Adjuvant Lung Trial.Clin Cancer Res,2005,11(13 Pt 2):5017S-5021S.
3Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase Ⅲ trials for patients with advanced non-small cell lung cancer: sobering results. J Clin Oncol, 2001, 19: 1734-1742.
4Schiller JH, Harrington D, Belani CP, et al. For the Eastern Cooperative Oncology Group: comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med, 2002, 346: 92-98.
5Mill AB, Hoogstrsten B, Staquet M, et al. Reporting results of cancer treatment. Cancer, 1981, 47: 207-214.
6Zhao H, Kanda K. Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Qual Life Res, 2000, 9: 129-137.
7Stephens RJ, Hopwood P, Girling DJ. Defining and analyzing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer, 1999, 79: 538-544.
8Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy-the fourth annual Joseph H Burchenal American Association for Cancer Research Clinical Reserarsh Award Lecture. Clin Cancer Res, 2000, 6: 747-753.
9Ciardiello F, Caputo R, Pomatico C, et al. Inhibition of growth factor production and angiogenesis in human cancer cell lines by ZD1839 (Iressa), a selective epidermal growth factor tyrosine kinase inhibitor. Clin Cancer Res, 2001, 7: 1459-1465.
10Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2003, 21: 2237-2246.
